Fulvestrant Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 250 mg/5 mL
Reference Brands: Faslodex® (EU & US)
Category:
Oncology Cancer Care
Fulvestrant is an injectable oncology drug used to treat hormone receptor-positive breast cancer. Available as 250 mg/5 mL IM injection in the US and EU.
Fulvestrant is available in Injection
and strengths such as 250 mg/5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Fulvestrant is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Fulvestrant can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fulvestrant is a potent estrogen receptor antagonist used in the treatment of HR+ metastatic breast cancer in postmenopausal women. It is indicated for patients whose cancer has progressed after prior endocrine therapy. Marketed as Faslodex®, Fulvestrant is available in both the US and EU as a 250 mg/5 mL intramuscular injection, typically administered as 500 mg monthly. It works by binding and degrading estrogen receptors, thereby inhibiting cancer cell growth. Widely used in oncology hospitals and cancer centers, Fulvestrant is a valuable product for B2B pharmaceutical distribution in the oncology and specialty injectable segments.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing